SCIENTIFIC publications

/cun/en/investigacion/publicaciones-cientificas/areaMain/02
  • Transforming Breast Cancer Together: European elections manifesto 2019 seizing the opportunities for breast cancer patients

    Cardoso F (1), Bușoi CS (2), Cattaneo I (3), Decise D (3), Cardone A (4), Filicevas A (4), Gentile E (5), Wierinck L (5), Knox S (6, Sebastiani S (7), Terrasanta C (7), Ujupan S (8), Ventura R (9), Wilson B (10), Rubio IT (11).

    (1) European School of Oncology (ESO) and Advanced Breast Cancer Global Alliance (ABC Global Alliance), Champalimaud Clinical Centre / Champalimaud Foundation, Lisbon, Portugal.
    (2) Member of the European Parliament, Brussels, Belgium.
    (3) Novartis, Origgio, Italy.
    (4) European Cancer Patient Coalition, Brussels, Belgium.
    (5) Former Member of the European Parliament, Brussels, Belgium.
    (6) Europa Donna- the European Breast Cancer Coalition, Milan, Italy.
    (7) Helsinn Healthcare SA, Lugano, Switzerland.
    (8) Eli Lilly and Company, Brussels, Belgium.
    (9) European School of Oncology (ESO), Advanced Breast Cancer Global Alliance (ABC Global Alliance), Bellinzona, Switzerland.
    (10) Working with Cancer, London, United Kingdom.
    (11) European Society of Breast Cancer Specialists (EUSOMA), European Society of Surgical Oncology (ESSO), Clinica Universidad de Navarra, Madrid, Spain.

    Breast 07 SEPTEMBER 2019

  • Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer

    Ponz-Sarvise M (1), Corbo V (2), Tiriac H (3), Engle DD (4), Frese KK (5), Oni TE (6), Hwang CI (3), Öhlund D (7), Chio IIC (8), Baker LA (3), Filippini D (3), Wright K (3), Bapiro TE (9), Huang PS (10), Smith PD (11), Yu KH (12), Jodrell DI (13), Park Y (3), Tuveson DA (14).

    (1) Medical Oncology, Clinica Universidad de Navarra, Universidad de Navarra.
    (2) Diagnostics and Public Health, ARC-Net Research Centre, University and Hospital Trust of Verona.
    (3) Cold Spring Harbor Laboratory.
    (4) Regulatory Biology Laboratory, Salk Institute for Biological Studies.
    (5) Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute.
    (6) Cancer Center, Cold Spring Harbor Laboratory.
    (7) Wallenberg Centre for Molecular Medicine, Umeå University.
    (8) Genetics and Development, Columbia University.
    (9) CRUK Cambridge Institute, University of Cambridge.
    (10) G&A, Cygnal Therapeutics.
    (11) Oncology Bioscience, AstraZeneca (United Kingdom).
    (12) Medicine, Memorial Sloan Kettering Cancer Center.
    (13) Cancer Research UK Cambridge Institute, University of Cambridge.
    (14) Cold Spring Harbor Laboratory

    Clinical Cancer Research 06 SEPTEMBER 2019

  • Functional Relationship between Leptin and Nitric Oxide in Metabolism

    Becerril S (1,2,3), Rodríguez A (4,5,6), Catalán V (7,8,9), Ramírez B (10,11,12), Unamuno X (13,14,15), Portincasa P (16), Gómez-Ambrosi J (17,18,19), Frühbeck G (20,21,22,23).

    (1) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (2) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (3) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (4) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (5) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (6) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (7) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (8) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (9) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (10) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (11) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (12) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (13) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (14) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (15) Medical Engineering Laboratory, University of Navarra, 31008 Pamplona, Spain.
    (16) Clinica Medica "A. Murri", Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Policlinico Hospital, 70124 Bari, Italy.
    (17) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (18) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (19) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (20) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (21) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (22) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (23) Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, 31008 Pamplona, Spain.

    Nutrients 06 SEPTEMBER 2019

  • Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma

    Naumann RW (1), Hollebecque A (2), Meyer T (3), Devlin MJ (3), Oaknin A (4), Kerger J (5), López-Picazo JM (6), Machiels JP (7), Delord JP (8), Evans TRJ (9), Boni V (10), Calvo E (10), Topalian SL (11), Chen T (12), Soumaoro I (12), Li B (12), Gu J (12), Zwirtes R (12), Moore KN (13).

    (1) Levine Cancer Institute, Atrium Health, Charlotte, NC.
    (2) Gustave Roussy, Villejuif, France.
    (3) UCL Cancer Institute, London, United Kingdom.
    (4) Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
    (5) Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
    (6) Clínica Universidad de Navarra, Navarra, Spain.
    (7) Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (IREC, Pole MIRO), UCLouvain, Brussels, Belgium.
    (8) IUCT-Oncopole, Toulouse, France.
    (9) University of Glasgow, Glasgow, United Kingdom.
    (10) START Madrid Centro Integral Oncológico Clara Campal, Madrid, Spain.
    (11) Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy and Kimmel Cancer Center, Baltimore, MD.
    (12) Bristol-Myers Squibb, Princeton, NJ.
    (13) Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, OK, and Sarah Cannon Research Institute, Nashville, TN.

    Journal of Clinical Oncology 05 SEPTEMBER 2019

  • Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma

    Rosiñol L (1), Oriol A (2), Rios R (3), Sureda A (4), Blanchard MJ (5), Hernández MT (6), Martínez-Martínez R (7), Moraleda JM (8), Jarque I (9), Bargay J (10), Gironella M (11), de Arriba F (12), Palomera L (13), Gonzalez-Montes Y (14), Marti J (15), Krsnik I (16), Arguiñano JM (17), Gonzalez ME (18), Gonzalez AP (19), Casado LF (20), Lopez-Anglada L (21), Paiva B (22), Mateos MV (23), San Miguel J (24), Lahuerta JJ (25), Bladé J (26).

    (1) Hospital Clínic, Institut d'investigacions Biomèdiques August Pi i Sunyer, Spain
    (2) Clinical Hematology, ICO - Hosp Germans Trias i Pujol, Spain.
    (3) Hospital Universitario Virgen de las Nieves, Spain.
    (4) Haematology, Institut Català d'Oncologia, Spain.
    (5) Hematology, Hospital Ramon y Cajal, Spain.
    (6) Hematology, Hospital Universitario de Canaria, Spain.
    (7) Hospital Clínico San Carlos.
    (8) Hematology., Hospital Universitario Virgen de la Arrixaca. University of Murcia, Spain.
    (9) Hematology, Hospital Universitari i Politècnic La Fe, Spain.
    (10) Hospital Universitario Son Llàtzer, Spain.
    (11) Hospital Universitario Vall d'Hebron, Spain.
    (12) Hematologia y Oncología Médica, Hospital General Universitario Morales Meseguer, Spain.
    (13) Hematology, Hospital Clínico, Spain.
    (14) hematologia ICO, hospital josep trueta, Spain.
    (15) Hospital la Mutua de Terrassa, Spain.
    (16) Hematology, Hospital Universitario Puerta de Hierro, Spain.
    (17) Complejo Hospitalario de Navarra, Spain.
    (18) Hematology, Hospital Cabueñes, Spain.
    (19) Hospital Universitario Central de Asturias, Spain.
    (20) Hematology, Hospital Virgen de la Salud, Spain.
    (21) Hospital Universitario, Spain.
    (22) Hematology, Clinica Universidad de Navarra, Spain.
    (23) Department of Hematology, University Hospital of Salamanca/IBSAL/Cancer Research Center, Spain.
    (24) Clinica Universidad de Navarra, Universidad de Navarra, Spain.
    (25) Hematology, Hospital Universitario 12 de Octubre, Spain.
    (26) Hospital Clínic Universitari, IDIBAPS, Barcelona, Spain.

    Blood 04 SEPTEMBER 2019

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra